LILLE, France & CAMBRIDGE, Mass.--(BUSINESS WIRE)--GENFIT (Alternext: ALGFT; ISIN: FR0004163111), a biopharmaceutical company at the forefront of drug discovery and development, focusing on the early diagnosis and preventive treatment of cardiometabolic and associated disorders, today announces plans to advance the development of GFT505, its leading drug candidate, following the completion of several clinical studies demonstrating its efficacy and safety in different patient populations.
